RxDoctor Payments Data

Parker McConville, MD

Family Medicine · Sanford, NCNPI 1295926251

Payments from drug & device makers

$13,188in general payments, 2019–2025

Across 791 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$1K
  • AstraZeneca$876
  • Boehringer Ingelheim$728
  • Lilly USA, LLC$680
  • Merck$574
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk162$2,667
AbbVie(2 entities)70$1,078
AstraZeneca56$876
Boehringer Ingelheim41$728
Lilly USA, LLC47$680
Merck40$574
Amarin Pharma, Inc.32$547
Pfizer31$508
Sanofi-aventis U.S. LLC32$502
Amgen32$440
GSK21$353
Abbott19$351
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$312
Vanda Pharmaceuticals Inc.6$274
Ardelyx, Inc.12$247
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)11$210
Bayer10$186
Johnson & Johnson(2 entities)14$184
Astellas Pharma US Inc11$183
Mylan Specialty L.p.8$167
Insulet Corporation6$162
Sumitomo Pharma America, Inc.6$127
Esperion Therapeutics, Inc.7$122
Exact Sciences6$117
Otsuka America Pharmaceutical, Inc.5$107
Biohaven Pharmaceuticals, Inc.7$104
Antares Pharma, Inc.5$98
Takeda Pharmaceuticals U.S.A., Inc.5$98
Novartis6$94
Sunovion Pharmaceuticals Inc.6$93
Nestle Healthcare Nutrition Inc.4$85
Corcept Therapeutics3$84
E.r. Squibb & Sons, L.L.C.4$75
Daiichi Sankyo Inc.3$60
Grifols USA, LLC2$44
Ironwood Pharmaceuticals, Inc2$42
Shield Therapeutics Inc1$36
Neos Therapeutics, LP3$35
Teva Pharmaceuticals USA, Inc.3$35
Eisai Inc.2$31
Xeris Pharmaceuticals, Inc.2$28
Clarus Therapeutics Inc.4$27
Tolmar, Inc.1$27
Kowa Pharmaceuticals America, Inc.2$26
UCB, Inc.1$22
Lifescan, Inc.1$21
Aimmune Therapeutics, Inc.1$21
Phathom Pharmaceuticals, Inc.1$20
Dexcom, Inc.1$19
The Binding Site Inc.1$19
Almatica Pharma LLC1$19
Inspire Medical Systems, Inc.1$16
Aytu Biopharma, Inc.1$16
Exeltis, USA Inc.1$15
Collegium Pharmaceutical, Inc.1$15
Viatris Specialty LLC1$15
Currax Pharmaceuticals LLC1$15
Hikma Pharmaceuticals USA1$14
Corium, LLC1$14
Phadia US Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,188 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,254
Medicare patients
92
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide261$310,091
JardianceEmpagliflozin202$199,611
JanuviaSitagliptin Phosphate70$79,095
MounjaroTirzepatide51$58,652
EliquisApixaban42$42,221
Janumet XrSitagliptin Phos/Metformin Hcl50$41,374
Tresiba Flextouch U-200Insulin Degludec12$30,771
RybelsusSemaglutide27$26,954
TrulicityDulaglutide23$25,601
FarxigaDapagliflozin Propanediol16$24,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$22,925
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$21,865
XareltoRivaroxaban31$20,081
Repatha SureclickEvolocumab20$15,349
MyrbetriqMirabegron11$8,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$2,667$340,408303 claims
Boehringer IngelheimJardiance, Spiriva Respimat$728$207,250216 claims
MerckJanuvia, Janumet Xr$574$120,469120 claims
Lilly USA, LLCMounjaro, Trulicity$680$84,25274 claims
PfizerEliquis$508$42,22142 claims
AstraZenecaFarxiga$876$24,39616 claims
GSKTrelegy Ellipta$353$22,92529 claims
Johnson & JohnsonXarelto$184$20,08131 claims
Astellas Pharma US IncMyrbetriq$183$8,25311 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$98$4,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Sanford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →